UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
NCT Number: NCT06560606
Acronym: UCAN CAN-DU
Status: RECRUITING
Study Type: OBSERVATIONAL
Conditions: Juvenile Idiopathic Arthritis
Sponsor: The Hospital for Sick Children
Collaborators: Canadian Institutes of Health Research (CIHR)|Genome Canada|Genome Alberta|The Arthritis Society, Canada|ReumaNederland|ZonMw: The Netherlands Organisation for Health Research and Development|Alberta Children's Hospital|Ontario Genomics
Sex: ALL
Age: CHILD, ADULT
Enrollment: 4100
Study Design: Observational Model: |Time Perspective: p
Start Date: 2018-08-24
Completion Date: 2027-03-30
Locations: Alberta Children's Hospital - University of Calgary, Calgary, Alberta, T3B 6A8, Canada|Stollery Children's Hospital, Edmonton, Alberta, T6G 2B7, Canada|BC Children's Hospital, Vancouver, British Columbia, V6H 3N1, Canada|Children's Hospital Health Science Centre Winnipeg, Winnipeg, Manitoba, R3A 1R9, Canada|Janeway Children's Hospital and Rehabilitation Centre, St John's, Newfoundland and Labrador, A1B 3V6, Canada|IWK Health Centre, Halifax, Nova Scotia, B3K 6R8, Canada|McMaster Children's Hospital, Hamilton, Ontario, L8N 3Z5, Canada|Children's Hospital, London Health Sciences Centre, London, Ontario, N6A 5W9, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, K1H 8L1, Canada|The Hospital for Sick Children, Toronto, Ontario, M5G 1E8, Canada|Montréal Children's Hospital, Montréal, Quebec, H4A 3J1, Canada|University of Saskatchewan, Saskatoon, Saskatchewan, S7N 5A2, Canada|Amalia Children's Hospital, Radboudumc, Nijmegen, Gelderland, 6525 GA, Netherlands|Sint Maartenskinderkliniek, Boxmeer, North Brabant, 6574 NA, Netherlands|Emma Children's Hospital, Amsterdam UMC, Amsterdam, North Holland, 1105 AZ, Netherlands|Willem-Alexander Children's Hospital, LUMC, Leiden, South Holland, 2333 ZA, Netherlands|Sophia Children's Hospital, EMC, Rotterdam, South Holland, 3015 CN, Netherlands|Beatrix Children's Hospital, UMCG, Groningen, 9713 GZ, Netherlands|Wilhelmina Children's Hospital, UMCU, Utrecht, 3584 EA, Netherlands

Summary:
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

Primary Outcome Measures: Prospectively collect essential clinical data elements from children with new onset JIA, Up to 24 months|Evaluate clinical outcomes associated with the use of therapeutic agents in children with JIA, Up to 24 months|Evaluate clinical outcomes associated with the de-prescribing of therapeutic agents in children with JIA, Up to 24 months|Prospectively collect essential clinical data elements from children with extreme phenotypes of JIA., Up to 12 months|Prospectively collect essential biological data elements from children with new onset JIA, Up to 24 months|Evaluate biological outcomes associated with the use of therapeutic agents in children with JIA, Up to 24 months|Evaluate biological outcomes associated with the de-prescribing of therapeutic agents in children with JIA, Up to 24 months|Prospectively collect essential biological data elements from children with extreme phenotypes of JIA, Up to 12 months|Prospectively collect essential socioeconomic data elements from children with new onset JIA, Up to 12 months|Evaluate the socioeconomic impact associated with the use of therapeutic agents in children with JIA, Up to 12 months|Evaluate the socioeconomic impact associated with the de-prescribing of therapeutic agents in children with JIA, Up to 24 months|Prospectively collect essential socioeconomic data elements from children with extreme phenotypes of JIA, Up to 12 months